神经药理学报 ›› 2023, Vol. 13 ›› Issue (2): 41-.DOI: 10.3969/j.issn.2095-1396.2023.02.007

• 研究论文 • 上一篇    下一篇

复合乳酸菌辅助二联方案治疗幽门螺杆菌感染的效果研究

程艳洁,王鹏飞   

  1. 福建医科大学附属南平第一医院消化内科,南平,353000,中国
  • 出版日期:2023-04-26 发布日期:2023-11-30
  • 通讯作者: 王鹏飞,主治医师,硕士研究生;研究方向:消化道疾病;E-mail:996954538@qq.com
  • 作者简介:程艳洁,副主任医师,硕士研究生;研究方向:消化道疾病;E-mail: chenyanjie2023@126.com
  • 基金资助:
    福建医科大学启航基金项目(No.2020QH1308)

Study on the Effect of Compound Lactic Acid Bacteria Adjuvant Regimen in the Treatment of Helicobacter Pylori Infection

CHENG Yan-jie, WANG Peng-fei   

  1. Department of Gastroenterology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, 353000, China

  • Online:2023-04-26 Published:2023-11-30

摘要:

目的:探讨复合乳酸杆菌辅助高剂量二联方案治疗成人幽门螺杆菌(helicobacter pylori,Hp)患者的临床研究。方法:选取福建医科大学附属南平第一医院门诊确诊Hp感染患者300例随机分为试验组(n=150)、对照组(n=150)两组:试验组采用高剂量二联标准方案伏诺拉生、阿莫西林、复合乳酸菌联合治疗;对照组单用高剂量二联标准方案伏诺拉生、阿莫西林进行治疗。两组治疗疗程均为10 d,评估两组抗Hp治疗的根除率和有效率、不良反应发生率。结果:记录疗程结束停药后4周以上复查13C呼气试验Hp根除率情况,复查胃镜溃疡愈合情况,慢性胃炎临床症状改善情况,药物不良反应发生率情况,两组组间比较差异无统计学意义(P>0.05),不良反应发生率比较差异有统计学意义(P<0.05)。结论:复合乳酸菌联合高剂量二联疗法治疗Hp感染,虽然不能提高Hp根除率,但能降低抗菌药物的不良反应发生率,服药品种少,患者易接受,提供依从性,值得临床开展。

关键词: 复合乳酸杆菌, 高剂量二联方案, 伏诺拉生, 阿莫西林, 联合治疗, 成人幽门螺杆菌, 临床研究

Abstract:

Objective: To investigate the clinical study of compound Lactobacillus assisted high-dose dual regimen in the treatment of adult Helicobacter pylori (Hp) patients. Methods: 300 patients diagnosed with Hp infection in the outpatient department of Nanping First Hospital Affiliated to Fujian Medical University were randomly divided into experimental group (n=150) and control group (n=150). The experimental group was treated with high-dose dual standard regimen of Venolazan, amoxicillin and complex lactic acid bacteria. The control group was treated with high dose dual standard regimen of Venolazan and amoxicillin alone. The treatment course of the two groups was 10 days, and the eradication rate, effective rate and incidence of adverse reactions of anti-HP treatment in the two groups were evaluated. Results: The Hp eradication rate of 13C breath test, the healing of gastroscopy ulcer, the improvement of clinical symptoms of chronic gastritis and the incidence of adverse drug reactions were recorded more than 4 weeks after the end of treatment course (P>0.05). There was no statistically significant difference between the two groups (P>0.05), while the incidence of adverse drug reactions was statistically significant (P<0.05). Conclusion: The combination of compound lactic acid bacteria and high-dose combination therapy for the treatment of Hp infection may not improve the eradication rate of Hp, but it can reduce the incidence of adverse reactions to antibiotics. The variety of medication used is small, easy for patients to accept, and provides compliance, which is worthy of clinical development.

Key words: complex lactobacillus, high dose dual regimen, vonorosen, amoxicillin, combination therapy, helicobacter pylori in adults, clinical research